Statins for Cardiovascular Prevention According to Different Strategies: A Cost Analysis
The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Abstract
Background Several studies have shown that treatment with HMG-CoA reductase inhibitors (statins) can reduce coronary heart disease (CHD) rates. However, the cost effectiveness of statin treatment in the primary prevention of CHD has not been fully established.Objective To estimate the costs of CHD prevention using statins in Switzerland according to different guidelines, over a 10-year period.Methods The overall 10-year costs, costs of one CHD death averted, and of 1 year without CHD were computed for the European Society of Cardiology (ESC), the International Atherosclerosis Society (IAS), and the US Adult Treatment Panel III (ATP-III) guidelines. Sensitivity analysis was performed by varying number of CHD events prevented and costs of treatment.Results Using an inflation rate of medical costs of 3%, a single yearly consultation, a single total cholesterol measurement per year, and a generic statin, the overall 10-year costs of the ESC, IAS, and ATP-III strategies were 2.2, 3.4, and 4.1 billion Swiss francs (SwF [SwF1 = $US0.97]). In this scenario, the average cost for 1 year of life gained was SwF352, SwF421, and SwF485 thousand, respectively, and it was always higher in women than in men. In men, the average cost for 1 year of life without CHD was SwF30.7, SwF42.5, and SwF51.9 thousand for the ESC, IAS, and ATP-III strategies, respectively, and decreased with age. Statin drug costs represented between 45% and 68% of the overall preventive cost. Changing the cost of statins, inflation rates, or number of fatal and non-fatal cases of CHD averted showed ESC guidelines to be the most cost effective.Conclusion The cost of CHD prevention using statins depends on the guidelines used. The ESC guidelines appear to yield the lowest costs per year of life gained free of CHD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lowering blood cholesterol levels using statins 10,11,23-25 and improving blood pressure control are also cost effective. 26,27”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [25]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290 · cited 3×
“Further, the SCORE [23] and PROCAM [24] algorithms are not validated for adults aged over 65 years of age, and the outcomes predicted by the algorithms are different: SCORE [23] predicts cardiovascular death, whereas PROCAM [24] and FRS [22] predict coronary heart disease (fatal and non-fatal).”
MethodAuthors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Writing Group Members, Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S. M., Ho, M., Howard, V., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.187998 · Cited by 3,711
Assmann, G., Cullen, P., & Schulte, H. (2002) · Circulation · doi:10.1161/hc0302.102575 · Cited by 1,541 · cited 5×
“For the PROCAM algorithm, we adapted estimates of for women considering that the absolute CHD risk in non-diabetic women was 4-fold lower compared with men of the same age, as suggested [24].”
MethodInfluentialTunstall-Pedoe, H., Kuulasmaa, K., Mähönen, M., Tolonen, H., & Ruokokoski, E. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04021-0 · Cited by 1,444
Firmann, M., Mayor, V., Vidal, P. M., Bochud, M., Pécoud, A., Hayoz, D., Paccaud, F., Preisig, M., Song, K. S., Yuan, X., et al. (2008) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-8-6 · Cited by 721
Self-citationEconomic burden of cardiovascular diseases in the enlarged European Union
Leal, J., Luengo-Fernández, R., Gray, A., Petersen, S., & Rayner, M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi733 · Cited by 698 · cited 4×
“In the EU they have been estimated at h169 billion annually, of which approximately 62% is due to healthcare expenses, 21% to productivity losses, and 17% to informal care of people with CVD.[1] In Switzerland, 15% of drugs prescribed in ambulatory practice and 17% of the pharmaceutical market are related to CVD.[4] P…”
BackgroundInfluential
Research works printed but not linked: 4
- Szucs, 1998, Eur Heart J, 19, M22
- Rickenbach, 1992, Médecine et Hygiène, 50, 350
- Martin, 2005, Rev Med Suisse, 1, 531
- Tran, 2007, Can J Clin Pharmacol, 14, e205
Cited by
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citationStatins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Statins in the primary prevention of cardiovascular disease
Reiner, Ž. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.80 · Cited by 189
Metadata
- Authors
- Ito, M. K., Nanchen, D., Rodondi, N., Paccaud, F., Waeber, G., Vollenweider, P., & Marques-Vidal, P.
- Affiliations
- University of Lausanne (CH)
- Centre Hospitalier Universitaire Vaudois (CH)
- Corresponding author
- Marques-Vidal, Pedro
- Venue
- American Journal Cardiovascular Drugs
- Published
- 2011-02
- Volume
- 11
- Issue
- 1
- Pages
- 33-44
- ISSN
- 1175-3277 (ISSN-L)
- OpenAlex
- W2118330255
- Cited by
- 11
- References
- 49
- Citations by year
- 2016: 3 · 2015: 1 · 2013: 3 · 2012: 1
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Cardiovascular Drugs (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- statins, coronary artery disease, primary prevention, cost-effectiveness, economic burden, cardiovascular disease prevention guidelines, ESC guidelines, Adult Treatment Panel III guidelines, Switzerland
- MeSH terms
- Adult, Aged, Coronary Disease, Cost-Benefit Analysis, Costs and Cost Analysis, Female, Humans, Male, Middle Aged, Health Care Costs, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, General Practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statins for Cardiovascular Prevention According to Different Strategies: A Cost Analysis. https://app.cochat.ai/papers/10.2165/11586760-000000000-00000
- The paper
- Ito, M. K., Nanchen, D., Rodondi, N., Paccaud, F., Waeber, G., Vollenweider, P., & Marques-Vidal, P. (2011). Statins for Cardiovascular Prevention According to Different Strategies: A Cost Analysis. American Journal Cardiovascular Drugs. https://doi.org/10.2165/11586760-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.